Surapol Issaragrisil

Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia

Giuseppe Saglio, Dong‐Wook Kim, Surapol Issaragrisil et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Andreas Hochhaus, Giuseppe Saglio, Timothy P. Hughes et al. · Leukemia · 2016 · 850 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +11

Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis

Hagop M. Kantarjian, Timothy P. Hughes, Richard A. Larson et al. · Leukemia · 2021 · 351 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +7

The epidemiology of aplastic anemia in Thailand

Surapol Issaragrisil, David W. Kaufman, Theresa Anderson et al. · Blood · 2005 · 197 citations · Full text

Medicine, Hematology, Pathology +12

Drugs in the aetiology of agranulocytosis and aplastic anaemia

David W. Kaufman, Judith P. Kelly, Jan M. Jurgelon et al. · European Journal Of Haematology · 1996 · 191 citations

Medicine, Hematology, Pharmacology +6